Next Article in Journal
Mortality Predictive Value of the C2HEST Score in Elderly Subjects with COVID-19—A Subanalysis of the COLOS Study
Next Article in Special Issue
Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients
Previous Article in Journal
The Role of Inflammation in Tinnitus: A Systematic Review and Meta-Analysis
Previous Article in Special Issue
How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease
 
 
Review

Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases

2nd Department of Paediatrics, Gastroenterology and Nutrition, Faculty of Medicine, Wroclaw Medical University, M. Sklodowskiej-Curie Str. 50/52, 50-367 Wroclawl, Poland
*
Author to whom correspondence should be addressed.
Academic Editors: Jose E. Mesonero and Eva Latorre
J. Clin. Med. 2022, 11(4), 994; https://doi.org/10.3390/jcm11040994
Received: 27 December 2021 / Revised: 5 February 2022 / Accepted: 8 February 2022 / Published: 14 February 2022
(This article belongs to the Special Issue Clinical Advances in Chronic Intestinal Diseases Treatment)
Selective interference with the functioning of the immune system consisting of the selective blockade of pro-inflammatory factors is a modern, promising, and developing strategy for the treatment of diseases resulting from dysregulation of the immune system, including inflammatory bowel disease. Inhibition of the TNF alpha pathway, group 12/23 cytokines, and lymphocyte migration is used in the treatment of severe or moderate ulcerative colitis and Crohn’s disease. Intracellular signal transduction by influencing the phosphorylation of SAT (signal transducer and activator of transcription) proteins remains in clinical trials. View Full-Text
Keywords: IBD; pro-inflammatory cytokines; lymphocyte migration; treatment IBD; pro-inflammatory cytokines; lymphocyte migration; treatment
MDPI and ACS Style

Kofla-Dłubacz, A.; Akutko, K.; Krzesiek, E.; Jamer, T.; Braksator, J.; Grębska, P.; Pytrus, T.; Stawarski, A. Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases. J. Clin. Med. 2022, 11, 994. https://doi.org/10.3390/jcm11040994

AMA Style

Kofla-Dłubacz A, Akutko K, Krzesiek E, Jamer T, Braksator J, Grębska P, Pytrus T, Stawarski A. Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases. Journal of Clinical Medicine. 2022; 11(4):994. https://doi.org/10.3390/jcm11040994

Chicago/Turabian Style

Kofla-Dłubacz, Anna, Katarzyna Akutko, Elżbieta Krzesiek, Tatiana Jamer, Joanna Braksator, Paula Grębska, Tomasz Pytrus, and Andrzej Stawarski. 2022. "Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases" Journal of Clinical Medicine 11, no. 4: 994. https://doi.org/10.3390/jcm11040994

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop